Hikal Limited

HIKAL

INE475B01022

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 06:00:47 2024-04-30 am EDT			5-day change	1st Jan Change
303.4 ^INR	-1.00%		-5.22%	-0.03%

Apr. 08	Hikal Limited agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million.	CI
Apr. 01	Hikal Limited Announces Completion of Tenure of Non-Executive, Independent Directors	CI

Hikal Limited agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million.

April 07, 2024

Hikal Limited (BSE:524735) agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million on April 8, 2024. The consideration consists of INR 41.24 million in cash. The transaction is expected to be completed on April 8, 2024.

Latest news about Hikal Limited

Hikal Limited agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million.	Apr. 07	CI
Hikal Limited Announces Completion of Tenure of Non-Executive, Independent Directors	Apr. 01	CI
Hikal Limited Announces the Demise of Board Member, Ranjit Gobindram Shahani	Mar. 09	CI
ICRA Affirms A+ Rating on Hikal; Outlook Stable	Mar. 05	MT
Hikal Limited Announces Appointment of Dharmesh Panchal as the Chief Technology Officer	Feb. 19	CI
Transcript : Hikal Limited, Q3 2024 Earnings Call, Feb 09, 2024	Feb. 09
Hikal Limited Declares Interim Dividend for the Financial Year 2023-2024, Payable on or Before March 9, 2024	Feb. 08	CI
Hikal Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Hikal Limited Announces Resignation of B. N. Kalyani as Director	Dec. 29	CI
Hikal Targets Acquisition of 26% Stake in Renewable Power Company FPEL Ujwal	Nov. 02	MT
Transcript : Hikal Limited, Q2 2024 Earnings Call, Nov 02, 2023	Nov. 02
Hikal Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 02	CI
Hikal Limited agreed to acquire 26% stake in Fpel Ujwal Private Limited for INR 41.2 million.	Nov. 01	CI
Hikal Limited Announces Executive Appointments	23-09-27	CI
Hikal Limited Approves the Appointment of Berjis M Desai and V. Ramachandra Kaundinya as an Independent Director	23-09-26	CI
Hikal Limited Approves the Declaration of Final Dividend for the Financial Year 2022-23	23-09-26	CI
Transcript : Hikal Limited, Q1 2024 Earnings Call, Aug 08, 2023	23-08-08
Hikal Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-08	CI
Hikal Limited Receives Communication from the Gujarat Pollution Control Board	23-07-23	CI
Hikal Books Higher Consolidated Profit in Fiscal Q4	23-05-30	MT
INDIA STOCKS-Indian shares rise to five-month high on improved global cues	23-05-30	RE
Transcript : Hikal Limited, Q4 2023 Earnings Call, May 29, 2023	23-05-29
Hikal Limited Announces Recommendation of Final Dividend for the Financial Year 2022-23	23-05-29	CI
Hikal Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-29	CI
Hikal Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-29	CI

Chart Hikal Limited

Duration

Period

More charts

Company Profile

Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-viral, anti-inflammatory, analgesic and anti-parasitic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone and NSAID. Its crop protection product categories include algaecide, biocide, fungicide, herbicide, insecticide and intermediate.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hikal Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

303.4 INR

Average target price

330 INR

Spread / Average Target

+8.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HIKAL LIMITED	-0.03%	448M
ELI LILLY AND COMPANY	+34.00%	704B
NOVO NORDISK A/S	+26.06%	577B
JOHNSON & JOHNSON	-7.75%	348B
MERCK & CO., INC.	+18.53%	327B
ABBVIE INC.	+4.95%	288B
ASTRAZENECA PLC	+15.02%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-4.89%	147B

Other Pharmaceuticals

Hikal Limited

Equities

HIKAL

INE475B01022

Pharmaceuticals

Hikal Limited agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million.

Latest news about Hikal Limited

Chart Hikal Limited

Company Profile

Income Statement Evolution

Ratings for Hikal Limited

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals